GlassScriptPhysician profile
Sudan Thapa
NPI 1831572684
$3,071.49
in general payments reported to CMS, 2019-2025
28 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2021: $171 · 2022: $109 · 2023: $123 · 2024: $466 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,096.11 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $231.27 | 2023-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $181.55 | 2021-2025 | Omnipod |
| Amgen INC. | $176.32 | 2021-2025 | Tepezza, Repatha, Prolia |
| Corcept Therapeutics | $143.34 | 2023-2025 | Korlym |
| Mannkind Corporation | $139.30 | 2024-2025 | |
| Medtronic, INC. | $129.23 | 2021-2025 | Minimed 780g |
| Abbott Laboratories | $112.41 | 2022-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $95.93 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Pfizer INC. | $89.96 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $87.51 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.49 | 2023-2025 | Jardiance, Tradjenta |
| Ascendis Pharma Endocrinology INC | $63.72 | 2024-2025 | Yorvipath |
| Lilly USA, LLC | $59.76 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Tandem Diabetes Care, INC. | $52.35 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $44.09 | 2025 | Twiist |
| Radius Health, INC. | $41.83 | 2024 | |
| Tolmar, INC. | $37.23 | 2025 | Jatenzo |
| Astrazeneca Pharmaceuticals LP | $36.86 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $34.15 | 2025 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $23.62 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $20.37 | 2022 | |
| Kyowa Kirin, INC. | $19.06 | 2025 | |
| Zealand Pharma US, INC. | $17.24 | 2021 | |
| Cequr Corporation | $17.15 | 2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $16.87 | 2021 | |
| Recordati_rare_diseases_inc. | $15.25 | 2025 | Isturisa |
| Novartis Pharmaceuticals Corporation | $14.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudan Thapa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.